Sexual behaviour and risk factors for the acquisition of human papillomavirus infections in young people in Italy: Suggestions for future vaccination policies

BMC Public Health

Volumn 12, Issue 1, 2012, Pages

  Panatto, Donatella ^a   Amicizia, Daniela ^a   Trucchi, Cecilia ^a   Casabona, Francesca ^a   Lai, Piero Luigi ^a   Bonanni, Paolo ^b   Boccalini, Sara ^b   Bechini, Angela ^b   Tiscione, Emilia ^b   Zotti, Carla Maria ^c   Coppola, Rosa Cristina ^d   Masia, Giuseppina ^d   Meloni, Angelo ^d   Castiglia, Paolo ^e   Piana, Andrea ^e   Gasparini, Roberto ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e UNIVERSITY OF SASSARI   (Italy)

Author keywords

Adolescents; HPV vaccination; Human papillomavirus; Sexual behaviour; Sexually transmitted diseases (STDs); Young people

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CONDOM; CONFIDENCE INTERVAL; DISEASE TRANSMISSION; FEMALE; HUMAN; ITALY; MALE; PAPILLOMAVIRUS INFECTION; QUESTIONNAIRE; RISK FACTOR; SEXUAL BEHAVIOR; URBAN POPULATION; UTILIZATION REVIEW; VACCINATION;

ADOLESCENT; CONDOMS; CONFIDENCE INTERVALS; FEMALE; HUMANS; ITALY; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUESTIONNAIRES; RISK FACTORS; SEXUAL BEHAVIOR; URBAN POPULATION; VACCINATION; YOUNG ADULT;

EID: 84864775367     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-12-623     Document Type: Article

References (44)

1. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Burchell AN, Winer RL, de Sanjosé S, Vaccine 2006 24 Suppl 3 52 61
2. Factors affecting transmission of mucosal human papillomavirus. Veldhuijzen NJ, Snijders PJ, Reiss P, Meijer CJ, van de Wijgert JH, Lancet Infect Dis 2010 10 862 874 10.1016/S1473-3099(10)70190-0 21075056
3. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. Rodríguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, Solomon D, Burk R, Proyecto Epidemiolgico Guanacaste Group, J Natl Cancer Inst 2008 100 513 517 10.1093/jnci/djn044 18364507
4. Vaccine against sexually transmitted human papillomavirus infection - the beginning of the end for cervical cancer. Lehtinen M, Paavonen J, CME Journal of Gynecologic Oncology 2004 9 210 213 (Pubitemid 350043437)
5. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA, Am J Epidemiol 2003 157 218 226 10.1093/aje/kwf180 12543621 (Pubitemid 36152435)
6. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Trottier H, Ferreira S, Thomann P, Costa MC, Sobrinho JS, Prado JC, Rohan TE, Villa LL, Franco EL, Cancer Res 2010 70 8569 8577 10.1158/0008-5472.CAN-10-0621 20978200
7. Age-related changes of the cervix influence human papillomavirus type distribution. Castle PE, Jeronimo J, Schiffman M, Herrero R, Rodrguez AC, Bratti MC, Hildesheim A, Wacholder S, Long LR, Neve L, Pfeiffer R, Burk RD, Cancer Res 2006 66 1218 1224 10.1158/0008-5472.CAN-05-3066 16424061 (Pubitemid 43165993)
8. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening. Adams M, Jasani B, Fiander A, Vaccine 2007 25 3007 3013 10.1016/j.vaccine.2007.01.016 17292517 (Pubitemid 46482732)
9. HPV vaccination against cervical cancer in women above 25years of age: key considerations and current perspectives. Castellsagué X, Schneider A, Kaufmann AM, Bosch FX, Gynecol Oncol 2009 115 Suppl 3 15 23 19819540
10. Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection. Gillison ML, Curr Opin Oncol 2009 21 439 444 10.1097/CCO. 0b013e32832f3e1b 19587593
11. Epidemiology of mucosal human papillomavirus infection and associated diseases. Trottier H, Burchell AN, Public Health Genomics 2009 12 291 307 10.1159/000214920 19684442
12. Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. Chen Z, Schiffman M, Herrero R, Desalle R, Anastos K, Segondy M, Sahasrabuddhe VV, Gravitt PE, Hsing AW, Burk RD, PLoS One 2011 6 20183 10.1371/journal.pone. 0020183 21673791
13. Efficacy of human papillomavirus (HPV)-16/18. AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Paavonen J, Naud P, Salmern J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group, Lancet 2010 376 9746 1054 20870098
14. Impact of quadrivalent human papillomavirus (HPV) types 6/11/16/18L1 virus-like particle vaccine on the incidence of abnormal pap tests and cervical procedures. [Abstract]. Huh WK, Quadrivalent HPV Vaccine Phase Iib/III Investigators, Gynecol Oncol 2008 108 3 Suppl1 10
15. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26years. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Munz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Sings HL, James M, Hesley TM, Barr E, J Infect Dis 2009 199 926 935 10.1086/597307 19236279
16. Skinner R, Apter D, Chow SN, Wheeler C, Dubin G, Cross-protection efficacy of Cervarix against oncogenic HPV types beyond HPV-16/18 Malmö, Sweden 2009 Abstract n° O-29.01 Presented at the 25th International Papillomavirus Conference 22920953
17. Natural History of Genital Warts: Analysis of the Placebo Arm of 2 Randomized Phase III Trials of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E, Haupt RM, Joura EA, J Infect Dis 2009 199 805 814 10.1086/597071 19199546
18. Intesa tra il governo, le Regioni e le Provincie autonome concernente Strategie per lofferta attiva del vaccino contro linfezione da HPV in Italia del 20 dicembre 2007 http://www.statoregioni.it/Documenti/DOC-016696-264%20csr.pdf
19. Human papillomavirus vaccination: what is the best choice? A comparison of 16 strategies by means of a decisional model. Gasparini R, Amicizia D, Manfredi P, Ansaldi F, Lucioni C, Gallelli G, Panatto D, Epidemiol Infect 2009 137 794 802 10.1017/S0950268808001441 18925989
20. Dynamics of HPV vaccination initiation in Flanders (Belgium) 2007-2009: a Cox regression model. Lefevere E, Hens N, De Smet F, Van Damme P, BMC Public Health 2011 11 470 10.1186/1471-2458-11-470 21672202
21. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, O'Flanagan D, Lopalco PL, D'Ancona F, Levy-Bruhl D, VENICE 2 project gatekeepers group, Euro Surveill 2010 15. pii: 19730
22. World Health Organization, Preparing for the Introduction of HPV Vaccine in the WHO European Region. Strategy paper http://www.euro.who.int/-data/assets/ pdf-file/0007/98746/E91432.pdf
23. The human papillomavirus (HPV) vaccine and cervical cancer: uptake and next steps. Sheinfeld Gorin SN, Glenn BA, Perkins RB, Adv Ther 2011 28 615 639 10.1007/s12325-011-0045-x 21818672
24. Missed clinical opportunities: Provider recommendations for HPV vaccination for 11-12year old girls are limited. Vadaparampil ST, Kahn JA, Salmon D, Lee JH, Quinn GP, Roetzheim R, Bruder K, Malo TL, Proveaux T, Zhao X, Halsey N, Giuliano AR, Vaccine 2011 29 8634 8641 10.1016/j.vaccine.2011.09.006 21924315
25. Self-reported sexual debut and behavior in young adults aged 18-24years in seven European countries: implicatioons for HPV vaccination programs. Crochard A, Luyts D, di Nicola S, Goncalves MA, Gynecol Oncol 2009 115 7 14 10.1016/j.ygyno.2009.06.003 19552945
26. HPV infections in adolescents. Moschicki AB, Dis Markers 2007 23 229 234 17627058
27. Sex, health, and years of sexually active life gained due to good health: evidence from two US population based cross sectional surveys of ageing. Lindau ST, Gavrilova N, BMJ 2010 340 810 10.1136/bmj.c810 20215365
28. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modeling analyses. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP, PLoS Med 2006 3 624 632 (Pubitemid 43807031)
29. Technical University of Denmark, Web pages that perform statistical calculations http://statpages.org
30. Open Source Epidemiologic Statistics for Public Health http://www.openepi.com
31. R Development Core Team, R: A language and environment for statistical computing Vienna, Austria: R Foundation for Statistical computing 2011 ISBN 3-900051-07-0, URL [ http://www.R-project.org/
32. Condom use and the risk of genital human papillomavirus infection in young women. Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, Koutsky LA, NEJM 2006 354 2645 2654 10.1056/NEJMoa053284 16790697
33. Consistent condom use is associated with lower prevalence of human papillomavirus infection in men. Nielson CM, Harris RB, Nyitray AG, Dunne EF, Stone KM, Giuliano AR, J Infect Dis 2010 202 445 451 10.1086/653708 20569156
34. Early adolescent sexual initiation as a problem behavior: a comparative study of five Nations. Madkour AS, Farhat T, Halpern CT, Godeau E, Gabhainn SN, J Adolesc Health 2010 47 389 398 10.1016/j.jadohealth.2010.02.008 20864009
35. Genital Trasmission of Human papillomavirus in recently formed heterosexual couples. Burchell AN, Coutlée F, Tellier PP, Hanley J, Franco EL, JID 2011 204 1723 1729 10.1093/infdis/jir644 21984739
36. Trasmission of human papillomavirus in heterosexual couples. Hernandez B, Wilkens L, Zhu X, Thompson P, McDuffie K, Shvetsov YB, Kamemoto LE, Killeen J, Ning L, Goodman MT, Emerg Infect Dis 2008 14 888 894 10.3201/eid1406.070616.2 18507898 (Pubitemid 351838596)
37. Concordance and transmission on human papillomavirus. Widdice L, Ma Y, Farhat S, Farhat S, Ma Y, Leonard AC, Moscicki AB, International Papillomavirus Conference Montreal Canada 2010 http://hpv2010.org
38. HPV transmission in heterosexually active couples over 12months. Mbulawa ZZA, Marais DJ, Coetzee D, Williamson AL, International Papillomavirus Conference Montreal Canada 2010 http://hpv2010.org
39. Gender differed factors affecting male condom use. A population-based study of 18-year-old Swedish adolescents. Novak DP, Karlsson RB, Int J Adolesc Med Health 2005 17 4 379 90 16445076 (Pubitemid 43072268)
40. Assessing perceived risk and STI prevention behavior: a national population-based study with special reference to HPV. Leval A, Sundstrom K, Ploner A, Dahlstrom LA, Widmark C, Sparén P, PLoS One 2011 6 6 20624 10.1371/journal.pone.0020624 21674050
41. Sexual behaviour in context: a global perspective. Wellings K, Collumbien M, Slaymaker E, Singh S, Hodges Z, Patel D, Bajos N, Lancet 2006 368 1706 1728 10.1016/S0140-6736(06)69479-8 17098090 (Pubitemid 46055217)
42. Sexual behaviour in Ligurian (Northern italy) adolescents and young people: suggestions for HPV vaccination policies. Panatto D, Amicizia D, Lugarini J, Sasso T, Sormani MP, Badolati G, Gasparini R, Vaccine 2009 27 6 A10 19480964
43. Stato di avanzamento della campagna vaccinale per lHPV: dati di copertura vaccinale al 30/06/2011 www.epicentro.iss.it/problemi/hpv/pdf/HPV-30-06-2011. pdf
44. National Services Scotland, Child Health http://www.isdscotlandarchive. scot.nhs.uk/isd/5921.html